Testosterone for midlife women: the hormone of desire?

  title={Testosterone for midlife women: the hormone of desire?},
  author={J. Shifren},
  volume={22 10},
Testosterone declines with aging, so most midlife women have "low" testosterone levels. Because libido also declines with aging, and distressing sexual problems peak at midlife, should midlife women with low libido and associated distress be treated with testosterone? This Practice Pearl reports clinical trial evidence, reviews the risks, and explains how testosterone might be used in a clinical setting. For women who may be considering a trial of testosterone therapy, limitations and adverse… Expand
8 Citations
Risks of Testosterone for Postmenopausal Women.
Transdermal testosterone therapy, dosed within premenopausal physiologic testosterone ranges, used alone or with menopausal hormone therapy for postmenopausal hypoactive sexual desire disorder, hasExpand
Androgens in postmenopausal women: a review
Abstract There is significant interest in the use of androgen therapy for postmenopausal women. This review provides background on endogenous androgens in women, describes factors that affectExpand
Methodological Challenges in Studying Testosterone Therapies for Hypoactive Sexual Desire Disorder in Women.
Testosterone trials in women have been limited by homogeneity in the study populations and outcomes measured, and the regulatory agency had posed a challenge to approve any testosterone treatment for women based on unproven concerns and a lack of regulatory guidance for drug developers. Expand
[The Role of Testosterone in The Improvement of Sexual Desire in Postmenopausal Women: An Evidence-Based Clinical Review].
At short-term, testosterone seems to improve sexual function in postmenopausal women, particularly sexual desire, but more studies with larger sample size and longer follow-up are needed to understand its long-term safety and effectiveness. Expand
Distressing Sexual Function at Midlife: Unmet Needs, Practical Diagnoses, and Available Treatments.
Clinicians are provided with a framework to approach the discussion of FSD, to clinically identify FSD through patient symptoms and physical signs, and to manage FSD in perimenopausal and postmenopausal patients with the available U.S. Food and Drug Administration-approved and off-label treatments. Expand
Evaluation and Management of Hypoactive Sexual Desire Disorder
The diagnosis and evidence-based treatment of low sexual desire in women with a focus on strategies that can be used efficiently and effectively in the clinic is reviewed, finding a biopsychosocial approach to evaluating and treating patients with HSDD is recommended. Expand
Pharmacotherapeutic options for the treatment of menopausal symptoms
The pharmacokinetics and pharmacodynamics of hormonal (androgens, estrogens, progestogens, tibolone, TSEC, SERMs) and non-hormonal treatments for menopausal symptoms are described and essential clinical trial data in humans is reported. Expand
4.01 – The Gonadal Axis: A Life Perspective
The purpose of this chapter is to describe the normal and pathological development, maturation, mature function, and senescence of the human HPG axis. Expand


Testosterone for low libido in postmenopausal women not taking estrogen.
In postmenopausal women not receiving estrogen therapy, treatment with a patch delivering 300 microg of testosterone per day resulted in a modest but meaningful improvement in sexual function. Expand
Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study
Testosterone patch treatment increased the frequency of satisfying sexual activity and sexual desire, decreased personal distress, and was well tolerated in naturally menopausal women with hypoactive sexual desire disorder. Expand
Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.
In the Intimate SM 1 study, the testosterone patch improved sexual function and decreased distress in surgically menopausal women with HSDD and was well tolerated in this trial. Expand
Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
The 300-microg/d testosterone patch increased sexual desire and frequency of satisfying sexual activity and was well tolerated in women who developed hypoactive sexual desire disorder after surgical menopause. Expand
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy.
In women who have undergone oophorectomy and hysterectomy, transdermal testosterone improves sexual function and psychological well-being in women who had impaired sexual function after surgically induced menopause. Expand
The role of androgen in the maintenance of sexual functioning in oophorectomized women.
It is suggested that androgen may be critical for the maintenance of optimal levels of sexual functioning in postmenopausal women. Expand
Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial
Testosterone administration in hysterectomized women with or without oophorectomy for 24 weeks was associated with dose and concentration-dependent gains in several domains of sexual function, lean body mass, chest-press power, and loaded stair-climb power. Expand
Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline.
Evidence supports the short-term efficacy and safety of high physiological doses of T treatment of postmenopausal women with sexual dysfunction due to hypoactive sexual desire disorder and no long-term safety data are lacking. Expand
Sexual Problems and Distress in United States Women: Prevalence and Correlates
The prevalence of distressing sexual problems peaked in middle-aged women and was considerably lower than the prevalence of sexual problems, which underlines the importance of assessing the popularity of sexually related personal distress in accurately estimating the prevalenceof sexual problems that may require clinical intervention. Expand
Effects of intranasal 17&bgr;-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women
The results of this study show that intranasal, similarly to transdermal, E2 administration does not increase serum CRP levels in postmenopausal women, and support the hypothesis that CRP increase during oral estrogen treatment is not mediated by the enhancement of interleukin-6 production by the immune cells but is rather caused by the hepatic first-pass metabolism effect. Expand